Acute Insomnia: Causes, Treatments, and When It Becomes Chronic

What Exactly Is Acute Insomnia?

Acute insomnia is defined by the International Classification of Sleep Disorders, Third Edition (ICSD-3) as dissatisfaction with sleep onset, duration, or quality for fewer than three months, occurring at least three nights per week, and causing measurable daytime impairment [1]. The key distinction from chronic insomnia is the three-month cutoff. Daytime impairment matters diagnostically, which means a patient who sleeps poorly but feels fine the next day does not technically meet criteria.

The American Academy of Sleep Medicine (AASM) notes that approximately 30 percent of the adult population reports acute insomnia symptoms each year, with a subset of around 10 percent meeting full diagnostic criteria [2]. Prevalence is higher in women, older adults, and people with pre-existing anxiety or depression. Shift workers carry roughly twice the population risk.

Precipitating events are almost always identifiable. Job loss, bereavement, medical illness, or even an anticipated stressful meeting can shorten sleep onset latency and fragment architecture. The physiological pathway typically involves hyperactivation of the hypothalamic-pituitary-adrenal (HPA) axis, elevated evening cortisol, and persistent cognitive arousal that keeps the default-mode network active when it should quiet for sleep [3]. Without addressing that arousal, the initial stressor can resolve while the conditioned hyperarousal persists, converting acute to chronic insomnia.

How Acute Insomnia Becomes Chronic: The 3-P Model

The Spielman 3-P model provides a clinically useful framework for understanding why some people recover and others do not. Predisposing factors (genetic sleep-reactivity, trait anxiety) set the baseline vulnerability. Precipitating factors (the stressor) push sleep over the threshold. Perpetuating behaviors then sustain the problem after the precipitant has gone.

Common perpetuating behaviors include spending excessive time in bed to "catch up," watching the clock during the night, daytime napping longer than 20 minutes, and catastrophizing about sleeplessness. A 2019 meta-analysis published in Sleep Medicine Reviews found that sleep-related cognitive distortions were the strongest predictor of acute-to-chronic conversion among 11 candidate variables studied in over 3,200 participants [4]. Eliminating perpetuating behaviors is exactly what CBT-I targets, which is why it outperforms sedatives in long-term outcomes.

The clinical bottom line: screen every acute insomnia patient for perpetuating behaviors at the first visit, not just the precipitant. A 10-minute structured interview using the Dysfunctional Beliefs and Attitudes About Sleep scale (DBAS-16) adds meaningful predictive data at no cost [5].

Diagnosing Acute Insomnia: Tools and Red Flags

Diagnosis is clinical. No sleep study is required for straightforward acute insomnia. The Insomnia Severity Index (ISI), a validated 7-item questionnaire, scores 0-28; a score of 15 or above indicates moderate-to-severe insomnia with a sensitivity of 86.1 percent and specificity of 87.7 percent against structured clinical interview [6]. The Pittsburgh Sleep Quality Index (PSQI) is an alternative, though it covers a 30-day window and is less specific for insomnia severity.

Red flags should prompt polysomnography (PSG) or actigraphy rather than empirical treatment:

• Witnessed apneas, snoring, or morning headaches suggesting obstructive sleep apnea (OSA)
• An irresistible urge to move the legs in the evening, relieved by movement, consistent with restless legs syndrome (RLS)
• A bed partner reporting rhythmic leg jerks during sleep, pointing to periodic limb movement disorder (PLMD)
• Excessive daytime sleepiness disproportionate to reported nighttime wakefulness
• Suspected circadian rhythm disorder (delayed or advanced sleep-wake phase)

A full-night in-laboratory PSG remains the gold standard for OSA diagnosis. The Apnea-Hypopnea Index (AHI) defines severity: 5-14 events per hour is mild, 15-29 moderate, and 30 or more events per hour is severe OSA [7]. Treating insomnia pharmacologically in a patient with undiagnosed severe OSA can suppress respiratory drive and worsen hypoxemia. This diagnostic step genuinely changes the treatment path.

First-Line Treatment: CBT-I

CBT-I is the recommended first-line treatment for both acute and chronic insomnia according to the American College of Physicians (ACP) 2016 Clinical Practice Guideline, which states: "ACP recommends that all adult patients receive cognitive behavioral therapy for insomnia (CBT-I) as the initial treatment for chronic insomnia disorder" [8]. The same principle applies to acute insomnia when perpetuating factors are already active.

CBT-I typically runs 6-8 sessions and includes five core components.

Sleep restriction therapy compresses time in bed to match actual sleep time, building sleep pressure. A patient sleeping 5 hours but spending 9 in bed is assigned a sleep window of 5.5 hours initially. Sleep efficiency is monitored weekly; when it exceeds 85 percent for five consecutive nights, the window expands by 15-30 minutes.

Stimulus control breaks the conditioned association between the bed and wakefulness. The patient goes to bed only when sleepy, gets out of bed after 20 minutes of wakefulness, and uses the bedroom only for sleep and sex.

Cognitive restructuring targets distorted beliefs. "I must get eight hours or I can't function" is replaced with evidence-based expectations about sleep variability and resilience.

Sleep hygiene education addresses modifiable behaviors: caffeine cutoff at 14:00, alcohol avoidance within three hours of bedtime, consistent wake time seven days per week, and light exposure management.

Relaxation training includes progressive muscle relaxation or diaphragmatic breathing to reduce physiological arousal.

A 2021 network meta-analysis in The Lancet Psychiatry, covering 154 randomized controlled trials and 26,155 participants, found CBT-I produced a standardized mean difference of -1.01 on the ISI versus placebo, compared with -0.47 for benzodiazepine receptor agonists [9]. CBT-I effects were maintained at 12-month follow-up; drug effects were not. Digital CBT-I programs (Sleepio, Somryst) have demonstrated efficacy comparable to therapist-delivered CBT-I for patients who cannot access in-person care [10].

Pharmacotherapy: Appropriate Use and Specific Agents

Medication has a role in acute insomnia, primarily as short-term bridging while behavioral strategies take hold, or when CBT-I is unavailable. The ACP guideline specifies that pharmacotherapy should be discussed only when CBT-I alone is insufficient [8]. That sequencing is the clinical standard.

Orexin receptor antagonists are the preferred pharmacological option for most adults. Suvorexant (Belsomra), FDA-approved in 2014, blocks orexin OX1 and OX2 receptors, reducing wakefulness drive rather than sedating the cortex. In a Phase 3 trial (N=1,021), suvorexant 20 mg reduced subjective time to sleep onset by 14 minutes versus placebo and cut wake-after-sleep-onset by 36 minutes at week 3 [11]. Lemborexant (Dayvigo), approved in 2019, showed a similar profile with a somewhat faster offset. Neither agent significantly suppresses REM sleep, a pharmacological advantage over older hypnotics.

Non-benzodiazepine GABA-A agonists (Z-drugs) include zolpidem (Ambien), eszopiclone (Lunesta), and zaleplon (Sonata). Zolpidem 5 mg (10 mg for men; women metabolize it more slowly) remains widely prescribed. The FDA issued a black box warning in 2019 covering rare but serious complex sleep behaviors including sleep-driving; patients with a history of parasomnias should not use Z-drugs [12]. Tolerance develops within 2-4 weeks of nightly use, which limits their utility for anything beyond short-term acute insomnia.

Low-dose doxepin (Silenor 3-6 mg) is FDA-approved specifically for sleep maintenance insomnia. At these doses it is a selective histamine H1 antagonist with minimal anticholinergic activity. A 12-week trial in older adults found doxepin 6 mg significantly improved wake-after-sleep-onset without next-morning residual impairment [13].

Melatonin and ramelteon act on MT1/MT2 receptors. Ramelteon 8 mg (Rozerem) is FDA-approved for sleep onset insomnia and carries no DEA scheduling, making it appropriate when abuse potential is a concern. Over-the-counter melatonin at 0.5-1 mg taken 1-2 hours before the intended sleep time produces modest but consistent sleep-onset benefits; doses above 5 mg do not improve efficacy and increase next-day grogginess in most adults [14].

Agents to avoid in acute insomnia include benzodiazepines as first choice (dependency risk), diphenhydramine (antihistamine tolerance within 4 nights, falls risk in older adults), and alcohol (fragments sleep architecture, suppresses REM, worsens OSA).

Obstructive Sleep Apnea as a Comorbidity

OSA and insomnia co-occur in approximately 39-58 percent of OSA patients, a condition sometimes called COMISA (comorbid insomnia and sleep apnea) [15]. This overlap matters because untreated OSA can cause fragmented sleep that mimics or perpetuates insomnia, and hypnotic use without CPAP therapy may worsen nocturnal hypoxemia.

The AASM recommends continuous positive airway pressure (CPAP) as first-line therapy for moderate-to-severe OSA [7]. CPAP titrated to eliminate apneas with an AHI below 5 resolves the respiratory fragmentation component; CBT-I then addresses residual conditioned hyperarousal. In COMISA patients, combining CPAP with CBT-I produces significantly better insomnia outcomes than CPAP alone. A randomized trial published in JAMA Internal Medicine (N=145) found that 4-month combined CPAP plus CBT-I reduced ISI scores by 9.6 points versus 4.4 points for CPAP alone (P<0.001) [16].

Restless Legs Syndrome and Periodic Limb Movement Disorder

Both conditions cause sleep-onset or sleep-maintenance difficulties that are frequently attributed to insomnia until a careful history or PSG reveals the underlying cause.

RLS (Willis-Ekbom disease) affects an estimated 5-10 percent of the U.S. adult population [17]. The four diagnostic criteria are: (1) an urge to move the legs, usually accompanied by uncomfortable sensations; (2) symptoms worse at rest; (3) partial or complete relief with movement; and (4) worsening in the evening or night. About 74 percent of RLS patients meet criteria for insomnia, but treating the insomnia without addressing RLS is ineffective.

First-line pharmacotherapy for moderate-to-severe RLS includes the alpha-2-delta ligands gabapentin enacarbil (Horizant, FDA-approved for RLS) and pregabalin, which outperform dopamine agonists in long-term studies due to a lower risk of augmentation [18]. Iron supplementation to achieve a serum ferritin above 75 mcg/L is recommended before initiating any pharmacotherapy, as iron deficiency is a correctable driver of RLS symptoms in a substantial proportion of patients [17].

Periodic limb movement disorder (PLMD) is characterized by repetitive stereotyped limb movements during NREM sleep, an index of 15 or more movements per hour in adults, causing either the patient or the bed partner significant disturbance. PSG is required for diagnosis since the patient is asleep during the events. PLMD and RLS share pathophysiology and treatment targets, though PLMD can occur independently. Dopaminergic agents (low-dose pramipexole, ropinirole) remain options for PLMD when augmentation risk is carefully monitored [19].

Special Populations

Older adults deserve particular attention. Sleep architecture shifts with age regardless of disease: slow-wave sleep decreases, sleep becomes more fragmented, and circadian phase advances. Sedating agents carry heightened risks of falls, cognitive impairment, and paradoxical excitation. The 2023 American Geriatrics Society Beers Criteria explicitly lists benzodiazepines and non-benzodiazepine hypnotics as potentially inappropriate for older adults, citing fall and fracture risk [20]. CBT-I adapted for older adults (CBT-I-OA) using slower pacing and modified sleep restriction produces effect sizes comparable to those seen in younger populations.

Perimenopause and menopause create a distinct insomnia phenotype driven by nocturnal vasomotor symptoms (hot flashes and night sweats) that fragment sleep and raise core body temperature during the sleep period. Menopausal hormone therapy (MHT) reduces vasomotor frequency and severity and improves objective sleep parameters, with transdermal 17-beta-estradiol showing the most consistent PSG data [21]. When MHT is contraindicated or declined, low-dose paroxetine 7.5 mg (Brisdelle) is FDA-approved specifically for menopausal vasomotor symptoms and may improve secondary sleep quality.

Pregnancy requires avoiding all Schedule IV hypnotics. CBT-I delivered digitally is safe, effective, and the preferred approach throughout gestation. Doxylamine 10 mg plus pyridoxine 10 mg (Diclegis/Bonjesta, already used for nausea) has some supporting data for sleep-onset difficulties in pregnancy, though prescribing specifically for insomnia is off-label [22].

When to Refer

Most acute insomnia is manageable in primary care or via telehealth with digital CBT-I tools and short-term pharmacotherapy. Referral to a sleep specialist is appropriate when:

• Symptoms persist beyond three months despite adequate CBT-I (chronic insomnia requiring full sleep workup)
• PSG findings suggest moderate-to-severe OSA, PLMD, or parasomnias
• RLS is refractory to first-line treatments or shows augmentation on dopamine agonists
• Excessive daytime sleepiness raises concern for narcolepsy or idiopathic hypersomnia
• Circadian rhythm disorder (confirmed by two-week actigraphy) requires phototherapy or chronobiotic protocols

A sleep diary kept for two weeks before the specialist appointment provides far more actionable data than the patient's subjective recall. Free validated templates are available through the AASM [2].

Monitoring Response to Treatment

The ISI score is the most practical office tool for tracking response. A clinically meaningful improvement is defined as a reduction of 6 or more points, and remission is defined as a score below 8 [6]. Check the ISI at baseline, at 4 weeks, and at 3 months. If the score has not dropped by 6 points after 4 weeks of CBT-I, add pharmacotherapy or intensify session frequency before attributing non-response to treatment failure.

Wrist actigraphy worn for 7-14 consecutive nights provides objective sleep efficiency data without the cost and inconvenience of PSG, and it is adequate for monitoring CBT-I progress in uncomplicated acute insomnia. Sleep efficiency below 85 percent on actigraphy after 8 weeks of CBT-I should prompt re-evaluation for undiagnosed OSA, mood disorder, or medication side effects perpetuating the problem [2].